Compare · PEPG vs WVE
PEPG vs WVE
Side-by-side comparison of PepGen Inc. (PEPG) and Wave Life Sciences Inc. (WVE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PEPG and WVE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- WVE is the larger of the two at $536.5M, about 1.4x PEPG ($370.4M).
- PEPG has been more active in the news (12 items in the past 4 weeks vs 6 for WVE).
- WVE has more recent analyst coverage (24 ratings vs 6 for PEPG).
- Company
- PepGen Inc.
- Wave Life Sciences Inc.
- Price
- -
- -
- Market cap
- $370.4M
- $536.5M
- 1M return
- -
- -19.38%
- 1Y return
- -
- -59.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2015
- News (4w)
- 12
- 6
- Recent ratings
- 6
- 24
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Wave Life Sciences Inc.
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Latest PEPG
- Amendment: SEC Form SCHEDULE 13D/A filed by PepGen Inc.
- Director Ra Capital Management, L.P. bought $43,125,000 worth of shares (8,625,000 units at $5.00) (SEC Form 4)
- PepGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Pricing of $125 Million Public Offering
- SEC Form 424B5 filed by PepGen Inc.
- PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
- PepGen upgraded by BofA Securities with a new price target
- PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by PepGen Inc.
Latest WVE
- Wave Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
- Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London
- SEC Form 10-Q filed by Wave Life Sciences Ltd.
- SEC Form 8-K filed by Wave Life Sciences Ltd.
- Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
- Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
- Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
- William Blair initiated coverage on Wave Life Sciences
- UBS initiated coverage on Wave Life Sciences with a new price target